However, no significant difference seen in efficacy or safety outcomes for clopidogrel versus no antiplatelet therapy
Adenoviral-Based COVID-19 Vaccines May Up Short-Term CV Risk
Increased incidence of myocardial infarction, pulmonary embolism seen in second week after first dose of Oxford-AstraZeneca vaccine
Blood Biomarker Linked to Incident VTE in COVID-19 Patients
Higher levels of soluble urokinase plasminogen activator receptor linked to incident venous thromboembolism independently of D-dimer
Relative Risk for CVT Up After AZD1222 COVID-19 Vaccine
Relative rates of hospital contacts for coagulation disorder, cerebrovascular disease increased after AZD1222 vaccination
FDA Limits Use of J&J COVID-19 Vaccine Due to Blood Clot Risk
With safer two-dose vaccines such as Pfizer and Moderna widely available, the one-dose J&J shot should be limited
COVID-19 Linked to Increased Risk for DVT, PE, Bleeding
Rate ratios were highest for critical COVID-19, and during first versus second and third pandemic waves in Sweden
Risk for Blood Clots After COVID-19 Vaccination Explored
Two studies show increase in intracranial venous thrombosis, thrombocytopenia for those younger than 70 years and in CVST after ChAdOx1-S
Scientists Report ‘Rogue Antibodies’ Behind Severe Clotting With COVID-19
Study authors suggest future research assess the potential benefits of screening COVID-19 patients for antiphospholipids and other autoantibodies
Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Thrombosis, Thrombocytopenia Syndrome Up After Ad26.COV2.S
Reporting rates 3.83 per million vaccine doses for Ad26.COV2.S versus 0.00855 per million for mRNA-based vaccines